AI Engines For more Details: Perplexity Kagi Labs You
Treatment of Parkinson's Disease: Bromocriptine mesylate is used as an adjunctive therapy in the management of Parkinson's disease, a progressive neurological disorder characterized by tremors, rigidity, bradykinesia (slowness of movement), and postural instability. It helps alleviate symptoms by acting as a dopamine agonist, mimicking the action of dopamine in the brain and compensating for its deficiency.
Treatment of Hyperprolactinemia: Bromocriptine mesylate is also used to treat hyperprolactinemia, a condition characterized by elevated levels of prolactin hormone in the blood. Elevated prolactin levels can lead to symptoms such as irregular menstrual periods, infertility, galactorrhea (abnormal breast milk production), and decreased libido. Bromocriptine mesylate works by inhibiting the release of prolactin from the pituitary gland.
Treatment of Acromegaly: Bromocriptine mesylate may be prescribed to manage acromegaly, a hormonal disorder characterized by excessive growth hormone (GH) production, typically caused by a benign tumor of the pituitary gland. By reducing GH secretion, bromocriptine mesylate helps control the symptoms of acromegaly, such as enlarged hands and feet, facial changes, and organ enlargement.
Menstrual Disorders: In addition to treating hyperprolactinemia, bromocriptine mesylate may be used to restore normal menstrual cycles in women with amenorrhea (absence of menstruation) or irregular menstrual periods due to hyperprolactinemia.
Diabetes Management: Bromocriptine mesylate has been investigated for its potential role in the management of type 2 diabetes mellitus. Some studies suggest that it may improve glycemic control by enhancing insulin sensitivity and reducing insulin resistance. However, its use in diabetes management is not as widespread as other medications due to mixed results and potential side effects.
Side Effects: Common side effects of bromocriptine mesylate may include nausea, vomiting, dizziness, headache, fatigue, drowsiness, and nasal congestion. These side effects are usually mild and transient but may require dose adjustments or discontinuation of the medication in some cases.
Cardiovascular Effects: Bromocriptine mesylate may rarely cause cardiovascular side effects such as hypotension (low blood pressure) and peripheral edema (swelling of the extremities). Patients should be monitored for signs of these adverse effects, especially when initiating therapy or adjusting the dosage.
Psychiatric Effects: Bromocriptine mesylate may also cause psychiatric side effects, including hallucinations, confusion, agitation, and psychotic disorders. These effects are more common at higher doses and in susceptible individuals.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Roseburia | genus | Decreases |
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Agathobacter | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Eggerthella | genus | Decreases |
| 0 | 1 | Odoribacter | genus | Decreases |
| 0 | 1 | Veillonella | genus | Decreases |
| 0 | 1 | Clostridium | genus | Decreases |
| 0 | 1 | Segatella | genus | Decreases |
| 0 | 1 | Clostridium perfringens A | no rank | Decreases |
| 0 | 1 | Clostridium perfringens C | no rank | Decreases |
| 0 | 1 | Clostridium perfringens CPE | no rank | Decreases |
| 0 | 1 | Clostridium perfringens D | no rank | Decreases |
| 0 | 1 | Clostridium perfringens B | no rank | Decreases |
| 0 | 1 | Clostridium perfringens E | no rank | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Agathobacter rectalis | species | Decreases |
| 1 | 0 | Parabacteroides merdae | species | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Bacteroides caccae | species | Decreases |
| 1 | 0 | Roseburia intestinalis | species | Decreases |
| 1 | 0 | Veillonella parvula | species | Decreases |
| 1 | 0 | Bacteroides ovatus | species | Decreases |
| 1 | 0 | Eggerthella lenta | species | Decreases |
| 1 | 0 | Segatella copri | species | Decreases |
| 1 | 0 | Bacteroides thetaiotaomicron | species | Decreases |
| 1 | 0 | Odoribacter splanchnicus | species | Decreases |
| 1 | 0 | Bacteroides fragilis | species | Decreases |
| 1 | 0 | Clostridium perfringens | species | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.2 | 0.2 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 2.1 | 0.3 | 6 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | 0.4 | 0.25 |
| Allergic Rhinitis (Hay Fever) | 0.9 | 0.9 | |
| Allergies | 1.5 | 0.7 | 1.14 |
| Allergy to milk products | 0.5 | 0.7 | -0.4 |
| Alopecia (Hair Loss) | 0.7 | 0.7 | |
| Alzheimer's disease | 2.4 | 3.4 | -0.42 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.5 | 0.4 |
| Ankylosing spondylitis | 1.5 | 0.3 | 4 |
| Anorexia Nervosa | 0.6 | 1.7 | -1.83 |
| Antiphospholipid syndrome (APS) | 0.5 | 0.5 | |
| Asthma | 2 | 1.1 | 0.82 |
| Atherosclerosis | 0.4 | 1.5 | -2.75 |
| Atrial fibrillation | 1.4 | 1.6 | -0.14 |
| Autism | 3 | 3.7 | -0.23 |
| Autoimmune Disease | 0.7 | -0.7 | |
| Barrett esophagus cancer | 0.3 | 0.3 | |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.3 | 0.3 | |
| Bipolar Disorder | 1.2 | 1.1 | 0.09 |
| Brain Trauma | 0.8 | -0.8 | |
| Cancer (General) | 0.6 | 0.5 | 0.2 |
| Carcinoma | 1.6 | 1 | 0.6 |
| Celiac Disease | 1.3 | 1.3 | 0 |
| Cerebral Palsy | 0.8 | 0.8 | 0 |
| Chronic Fatigue Syndrome | 1.5 | 2.7 | -0.8 |
| Chronic Kidney Disease | 1.7 | 1.2 | 0.42 |
| Chronic Lyme | 0.8 | -0.8 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
| Chronic Urticaria (Hives) | 0.5 | 0.3 | 0.67 |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.5 | -0.25 |
| Cognitive Function | 1.5 | 1 | 0.5 |
| Colorectal Cancer | 2.7 | 1.6 | 0.69 |
| Constipation | 0.3 | 0.5 | -0.67 |
| Coronary artery disease | 0.3 | 2.2 | -6.33 |
| COVID-19 | 3.1 | 3.8 | -0.23 |
| Crohn's Disease | 3.1 | 2.3 | 0.35 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.8 | -0.8 | |
| deep vein thrombosis | 0.7 | 0.8 | -0.14 |
| Denture Wearers Oral Shifts | 0.3 | 0.3 | |
| Depression | 3.5 | 3.7 | -0.06 |
| Eczema | 0.5 | 0.3 | 0.67 |
| Endometriosis | 0.7 | 1.1 | -0.57 |
| Eosinophilic Esophagitis | 0.3 | -0.3 | |
| Epilepsy | 0.5 | 1.3 | -1.6 |
| erectile dysfunction | 0.5 | 0.5 | |
| Fibromyalgia | 2.1 | 1.7 | 0.24 |
| Functional constipation / chronic idiopathic constipation | 1.9 | 2.2 | -0.16 |
| gallstone disease (gsd) | 1 | 0.5 | 1 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 0.4 | |
| Generalized anxiety disorder | 0.6 | 1 | -0.67 |
| giant cell arteritis | 0.2 | -0.2 | |
| Gout | 1.3 | 0.2 | 5.5 |
| Graves' disease | 1 | 1.1 | -0.1 |
| Gulf War Syndrome | 0.2 | 0.3 | -0.5 |
| Halitosis | 0.6 | 0.6 | |
| Hashimoto's thyroiditis | 1.2 | 0.3 | 3 |
| Heart Failure | 1.1 | 1.2 | -0.09 |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.3 | 0.3 | 0 |
| High Histamine/low DAO | 0.8 | 0.8 | |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 0.3 | 0.7 | -1.33 |
| hypertension (High Blood Pressure | 1.3 | 1.5 | -0.15 |
| Hypothyroidism | 0.3 | 0.3 | 0 |
| Hypoxia | 1 | 0.2 | 4 |
| IgA nephropathy (IgAN) | 1 | 2 | -1 |
| Inflammatory Bowel Disease | 2.4 | 3.9 | -0.63 |
| Insomnia | 0.6 | 1.4 | -1.33 |
| Intelligence | 0.7 | 0.2 | 2.5 |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 2.4 | 2 | 0.2 |
| ischemic stroke | 1 | 1.1 | -0.1 |
| Liver Cirrhosis | 3 | 1.3 | 1.31 |
| Long COVID | 2.5 | 2.1 | 0.19 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.4 | 0.4 | |
| ME/CFS with IBS | 0.2 | 0.3 | -0.5 |
| ME/CFS without IBS | 0.7 | 1 | -0.43 |
| Menopause | 0.2 | 0.5 | -1.5 |
| Metabolic Syndrome | 2.6 | 2.2 | 0.18 |
| Mood Disorders | 3.8 | 3.6 | 0.06 |
| multiple chemical sensitivity [MCS] | 0.3 | 0.3 | |
| Multiple Sclerosis | 1.2 | 3.2 | -1.67 |
| myasthenia gravis | 0.7 | -0.7 | |
| neuropathic pain | 0.3 | 1.4 | -3.67 |
| Neuropathy (all types) | 0.3 | 1.4 | -3.67 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | 1.8 | 0 |
| NonCeliac Gluten Sensitivity | 0.6 | 0.3 | 1 |
| Obesity | 3.2 | 2.2 | 0.45 |
| obsessive-compulsive disorder | 1.4 | 1.1 | 0.27 |
| Osteoarthritis | 0.5 | 0.3 | 0.67 |
| Osteoporosis | 1.6 | 0.3 | 4.33 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 2.2 | 2.9 | -0.32 |
| Polycystic ovary syndrome | 2.9 | 1.3 | 1.23 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.2 | |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0.3 | 0.2 | 0.5 |
| Primary sclerosing cholangitis | 1.5 | 1.3 | 0.15 |
| Psoriasis | 0.6 | 2.8 | -3.67 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.8 | 2.4 | -0.33 |
| Rosacea | 0.7 | -0.7 | |
| Schizophrenia | 2.1 | 1.8 | 0.17 |
| Sjögren syndrome | 1.5 | 1 | 0.5 |
| Sleep Apnea | 1.1 | -1.1 | |
| Slow gastric motility / Gastroparesis | 0.6 | 0.6 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.8 | 0.8 | |
| Stress / posttraumatic stress disorder | 1.5 | 1.5 | 0 |
| Systemic Lupus Erythematosus | 1.9 | 0.8 | 1.37 |
| Tic Disorder | 0.3 | 0.2 | 0.5 |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 1.8 | 1.7 | 0.06 |
| Type 2 Diabetes | 2.6 | 2.1 | 0.24 |
| Ulcerative colitis | 1.7 | 2.9 | -0.71 |
| Unhealthy Ageing | 1 | 1.9 | -0.9 |
| Vitiligo | 0.8 | 0.6 | 0.33 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
